]>
IRCT138806142420N1 IRCT 2009-10-25 Research deputy of Shiraz University of Medical Sciences Comparison of the effects of Bromocriptine and Cabergoline on the occurrence of pregnancy in infertile women Fertility outcome of hyperprolactinemic infertile women undergoing induction of ovulation for intrauterine insemination (IUI): A comparison between Bromocriptine and Cabergoline 2005-03-01 anticipated 188 Complete https://irct.ir/trial/2134 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 3 Hyperprolactinemic infertile women. Intervention 1: Bromocriptine 2.5 mg BID. Intervention 2: Cabergoline 0.25 mg twice a week.
public Seyed-Mohammad Fereshtehnejad
Medical Faculty, Iran University of Medical Sciences and Health Services, Hemmat highway
Tehran Iran (Islamic Republic of) +98 21 2275 6035 mohammad@stu.iums.ac.ir Iran University of Medical Sciences and Health Services scientific Lida Babakhani
Research Deputy, Central department of Shiraz University of Medical Sciences and Health Services, Zand St.
Shiraz Iran (Islamic Republic of) +98 21 2230 1913 dr_lida_babakhani@yahoo.com Shiraz University of Medical Sciences and Health Services Iran (Islamic Republic of) Inclusion criteria: 1) Primary or secondary infertility, 2) Hyperprolactinemia with or without galactorrhea (prolactin>20ng/ml), 3) Normal HA except high prolactin level, normal HSG or laparoscopy and normal SA. Exclusion criteria: 1) other causes of infertility such as tubal factor, male factor or unexplained infertility, 2) nausea, vomiting, orthostatic hypotension, chronic hypertension, headache, 3) sensitivity to ergot derivatives, 4) macroadenoma of pituitary gland, 5) previous use of bromocriptine or cabergoline 19 years 38 years Female N97.0 Female infertility associated with anovulation Treatment - Drugs Treatment - Drugs Bromocriptine 2.5 mg BID Cabergoline 0.25 mg twice a week The occurrence of pregnancy. Timepoint: At 6-7 weeks of gestational age. Method of measurement: Transvaginal sonography. Serum prolactin level. Timepoint: 4 weeks after treatment. Method of measurement: Laboratory measurment. Treatment side effects. Timepoint: Every 4 weeks. Method of measurement: Check list. Research deputy of Shiraz University of Medical Sciences Approved 2007-04-21 Ethics committee of Shiraz University of Medical Sciences Research deputy, 7th floor, Central department of Shiraz University of Medical Sciences, Zand St. Shiraz Iran (Islamic Republic of)